Codagenix Announces Close of $25 million Extension of Series B

Funding supports continued clinical studies for pediatric RSV and universal influenza vaccine candidates as well as expanded indications for oncology vertical FARMINGDALE, N.Y. and CAMBRIDGE, Mass., Feb. 15, 2023 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Venture Capital Codagenix, CodaVax-RSV, respiratory syncytial virus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news